Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on June 25, 2019, covering events occurring on June 21, 2019. The company is an emerging growth company incorporated in Delaware with its principal executive offices in San Francisco, California. Its common stock trades on The NASDAQ Capital Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material event reported is the resolution of a Nasdaq listing deficiency. Previously, the company faced potential delisting because its stock bid price closed below the required $1.00 minimum for 30 consecutive business days. On June 21, 2019, the company received notification from the Nasdaq Office of General Counsel that the minimum bid price deficiency had been cured. Consequently, the company is now in compliance with all applicable listing standards, and the previously scheduled hearing before the Nasdaq Hearings Panel was cancelled as moot.
Outlook, Risks, and Management Commentary
Management confirmed that Nasdaq has determined to continue the listing of the company's securities. A press release regarding this resolution was issued on June 24, 2019. The filing does not provide specific forward-looking guidance, new risk factors, or details on unusual items beyond the resolution of the listing status.
Investor Verification Checklist
- Verify the current trading price of JAGX to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the press release dated June 24, 2019 (Exhibit 99.1) for additional context on the cure mechanism.
- Monitor future filings for any recurrence of listing deficiencies or financial performance updates.